Track Your CD4 Count and Viral Load! Use TheBody.com's New Health Tracker!

HIV/AIDS Basics & Prevention

Just Diagnosed

HIV Treatment

Living With HIV

AIDS Policy & Activism

HIV Around the World

Conference Coverage

Kaletra (Lopinavir/Ritonavir)

The Basics | News | Research

See also: Medication Side Effects | Drug Interactions

Show Archived (Historical) Articles

Brand Name:	Kaletra
Generic Name:	Lopinavir/Ritonavir, LPV/RTV
Adult Single Dose*:	Two tablets (400 mg/100 mg) twice daily or 4 tablets (800 mg/200 mg) once daily
Food & Liquid Restrictions:	Take with or without food. Side effects may be lessened with food.
Drug Class:	PI
* This recommendation is for patients starting HIV treatment. A different dose is recommended for treatment experienced patients.

The Basics

An Overview of Kaletra (Lopinavir/Ritonavir) (Regularly Updated)
To read PDF, click here
From U.S. National Institutes of Health
Lopinavir + Ritonavir (Kaletra) (April 9, 2009)
To read PDF, click here
From AIDS InfoNet
Medication Guide for Kaletra (April 6, 2009)
Created by the makers of Kaletra specifically for people with HIV. Includes a rundown of possible side effects, reasons why Kaletra may not be a good fit for everybody, meds to avoid while taking Kaletra, and tips on how to maximize the chances Kaletra will work well.
From Abbott Laboratories
Kaletra (March/April 2009)
To read PDF, click here
In Positively Aware, from Test Positive Aware Network
Patient Information About Kaletra (Lopinavir/Ritonavir) Tablets and Oral Solution (PDF) (April 2009)
From Abbott Laboratories
Patient Frequently Asked Questions (November 2007)
Information about the new Kaletra (lopinavir/ritonavir) tablets.
From Abbott Laboratories
Kaletra (Lopinavir/Ritonavir) (September 28, 2007)
Basic information on dosing schedules and side effects.
From U.S. Department of Veterans Affairs
Patient Information About Kaletra (Lopinavir/Ritonavir) Capsules (PDF) (July 2007)
From Abbott Laboratories
Lopinavir (Kaletra) (August 15, 2006)
From AIDS Treatment Data Network

News

Labeling Changes for Kaletra Reflecting New QT/QTC Interval and PR Interval Prolongation Information (April 7, 2009)
HIVers who have "electrical" problems with their heart -- problems that impact their heart rhythm, for instance -- should be wary of using Kaletra (lopinavir/ritonavir), according to new information added to the drug's official labeling.
From U.S. Food and Drug Administration
WHO Approves Heat-Stable, Generic Version of Abbott's Kaletra (February 26, 2009)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
Abbott Drug Pricing Condemned by AIDS Advocates in International Protests (January 27, 2009)
In coordinated actions, protesters in Mexico, Colombia and the U.S. demand that Abbott lowers the price of its key AIDS drug Kaletra; advocates otherwise vow to seek compulsory licenses in Colombia and Mexico; in U.S., AHF to also premiere 60-second video parody blasting Abbott and CEO Miles White on YouTube and place spot as TV commercial on select Chicago-area television stations.
From AIDS Healthcare Foundation
New Pediatric Dosing Information for Kaletra, Patients 14 Days to 6 Months and 12-18 Years of Age and Update Information on Coadministration With Midazolam (PDF) (June 23, 2008)
From U.S. Food and Drug Administration
Newly-Unsealed Documents Shed Light on Abbott Labs' 400% Norvir Price Hike (May 12, 2008)
Union, consumer groups decry Abbott for putting profits before HIV/AIDS patients' needs
In A Closer Walk: A Film by Robert Bilheimer, from Community Catalyst
Abbott Receives FDA Approval for Lower-Dose of Kaletra for Children (November 13, 2007)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
Kaletra and Accidental Overdose in Children (PDF) (August 16, 2007)
Direct Healthcare Professional communication on Kaletra (lopinavir/ritonavir) solution and accidental overdose in children.
From Abbott Laboratories
Abbott, FDA Warn About Possible Overdose of Antiretroviral Kaletra in Children (August 15, 2007)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
Student Global AIDS Campaign Responds to Abbott's Decision to Reduce Price of Kaletra in Low and Middle Income Countries (April 10, 2007)
From Student Global AIDS Campaign

Research

Jens Lundgren, M.D., Discusses New Findings Regarding MI Risk of Specific Antiretrovirals (February 9, 2009)
The latest data from D:A:D indicate that lopinavir/ritonavir does increase myocardial infarction risk, but efavirenz, nevirapine and tenofovir do not. In this interview, Jens Lundgren, M.D., and HIV advocate Jeff Berry take part in a fascinating discussion on the new findings and their possible underlying causes.
In The 16th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Does Kaletra Monotherapy Work? Depends on Who You Ask (October 27, 2008)
Project Inform says the latest findings on Kaletra monotherapy are anything but positive.
From Project Inform
Drug/Drug Interaction Between Lopinavir/Ritonavir and Rosuvastatin in Healthy Volunteers. (February 14, 2008)
In Journal of Acquired Immune Deficiency Syndromes
Atazanavir Noninferior to Lopinavir in Treatment-Naive HIV-Infected People (February 6, 2008)
From The Body PRO
Lopinavir/Ritonavir Monotherapy or Plus Zidovudine and Lamivudine in Antiretroviral-Naive HIV-Infected Patients (January 30, 2008)
In AIDS
EACS: Kaletra Monotherapy May Need Excellent Adherence to Work (October 31, 2007)
In aidsmap.com
ATAZIP: Switching Away From Lopinavir/Ritonavir (July 25, 2007)
Switching from lopinavir/ritonavir (Kaletra) to atazanavir (Reyataz)/ritonavir (Norvir) maintains virologic efficacy and leads to sustained improvements in lipid levels. Graeme Moyle, M.D., reports.
In 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, from The Body PRO
Darunavir Superior to Lopinavir in 48-Week Study in Treatment-Experienced Patients (July 6, 2007)
From aidsmap.com
Kaletra-Based Regimens May Suppress Viral Load Despite Missed Doses (May 1, 2007)
In Journal of Acquired Immune Deficiency Syndromes
Metabolic Complications: A CROI Round-Up (February 28, 2007)
Includes an analysis of research examining lopinavir/ritonavir vs. efavirenz, the use of growth hormone releasing factor to treat fat gain, the link between cardiovascular disease and HIV treatment, the use of ezetimibe (a choleserol-reducing agent) and the latest on bone health in HIV-infected patients.
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Predictors of Virologic Rebound on Lopinavir/Ritonavir Monotherapy (February 28, 2007)
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
Resistance Analysis of Lopinavir/Ritonavir Maintenance Therapy Study (February 27, 2007)
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
The GEMINI Study: Are Saquinavir + Ritonavir and Lopinavir/Ritonavir Twins? (November 16, 2006)
In 8th International Congress on Drug Therapy in HIV Infection
Long-Term Lopinavir/Ritonavir Treatment and CD4+ Cell Responses (September 29, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
Reducing the Dose of Lopinavir/Ritonavir Is Associated With Low-Level Viremia (September 29, 2006)
In 46th Interscience Conference on Antimicrobial Agents and Chemotherapy
Potency of Boosted Fosamprenavir Matches Lopinavir/Ritonavir for First-Line Therapy (August 17, 2006)
In XVI International AIDS Conference
Switching From Lopinavir/Ritonavir to Unboosted Atazanavir May Yield Benefits, but Verdict Remains Uncertain (August 17, 2006)
In XVI International AIDS Conference
Treating Patients With Lopinavir/Ritonavir Alone Still Risky (August 17, 2006)
In XVI International AIDS Conference
Acid-Reducing Agents Reduce Atazanavir Drug Levels but Not Lopinavir/Ritonavir Levels (February 7, 2006)
In The 13th Conference on Retroviruses and Opportunistic Infections
During the Third Trimester of Pregnancy Lopinavir/Ritonavir Dose Should Be Increased, Study Finds (February 6, 2006)
In The 13th Conference on Retroviruses and Opportunistic Infections
Dosing Agenerase + Kaletra -- Trying to Juggle, Walk and Chew Gum All at the Same Time (March/April 2004)
A study presented at CROI 2004 bolsters support for the use of therapeutic drug monitoring to customize dosing.
In Positively Aware, from Test Positive Aware Network

The Body is a service of Body Health Resources Corporation, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Body Health Resources Corporation, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.